(New York, NY) – June 12, 2014 – AiCure, an artificial intelligence company providing advanced facial recognition solutions to monitor medication adherence, was invited to speak at the 2014 National TB Conference in Atlanta and to demonstrate the use of AiViewTM for monitoring treatment for latent and active TB. Adam Hanina, CEO, showcased the technology and its applicability in accurately monitoring patients being treated for TB. Traditionally, treatment for active TB has required patients to be directly observed while taking their medication. While effective in achieving high adherence rates, the high cost and resource-intensive nature of DOT has strained health budgets and led health departments to look for alternatives. Recent studies have also shown that even for shorter treatment courses such as the newly-approved three-month regimen for latent TB, a major barrier to adoption by patients has been the requirement for DOT.
AiViewTM, which is available in multiple languages as an app on smartphones and tablets, visually and automatically confirms that the right patient is taking the right medication at the right time. Unlike video dosing which is already being used across several states, AiViewTM does not require human review, and significantly lowers the cost of implementation.